Anti-reflux mucosal ablation significantly benefits patients with reflux-predominant GERD unresponsive to PPI therapy.

• 71.4% of patients receiving mucosal ablation reported at least a 50% improvement in quality of life after 6 months, compared to just 3.6% in the sham group (p<0.001).
• Significant reductions in heartburn, regurgitation, and reflux episodes were observed, with 35.7% of patients able to discontinue PPIs.

This technique may change the surgical approach to managing refractory GERD.

• Improvements in endoscopic findings were noted, further supporting its efficacy.

Social determinants significantly affect short-term outcomes after gastrectomy for gastric adenocarcinoma, highlighting disparities in care.

• Black patients are 25% less likely and Hispanic patients are 29% less likely to experience extended hospital stays compared to white patients.
• Higher education levels correlate with a 19% increased risk of extended stays and a 26% increased risk of readmissions.

Surgeons should consider social factors in patient selection and postoperative planning to improve outcomes.

• Asian patients have 40% lower mortality rates compared to white patients.

Recent updates in multimodal treatment are reshaping gastric cancer care, impacting surgical strategies and patient outcomes.

• Laparoscopic and robotic gastrectomy are now standard in Asia, supported by major trials like JCOG0912 and K-LASS02.
• The FLOT chemotherapy regimen is becoming the global standard, while SOX and XELOX gain traction in Asia.

Surgeons should consider integrating immunotherapy based on emerging trial results for select patients.

• Ongoing trials are studying the role of conversion surgery in stage IV cases, highlighting the need for personalized multi-disciplinary approaches.